WXWenlong Xing

Wenlong Xing

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Wenlong Xing has a total of 25 co-authors. Here are the top co-authors by number of shared publications:

  • Juju Shang

    Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, China

    2 shared publications
  • Haoyue Shi

    Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China

    1 shared publication
  • He-Yi Zhang

    Beijing hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, PR China

    1 shared publication
  • Hong-Xu Liu

    Beijing hospital of Traditional Chinese Medicine, Capital Medical University, Beijing 100010, PR China

    1 shared publication
  • Hongxu Liu

    Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China

    1 shared publication
  • Hongxu Liu

    Beijing Hospital of Traditional Chinese Medicine, Capital Medical University

    1 shared publication

Latest Publications

  • Open Access

    Astragalus membranaceus injection activates mitophagy and protects mitochondrial function in chronic heart failure via inhibiting AKT/mTOR pathway

    by Sinai Li, Juju Shang, Wenlong Xing, Mingxue Zhou, Shenglei Qiu, Weihong Liu, Lei Zhang, Haoyue Shi, Huanning Niu, Songtao Kuang, et al.

    To investigate the effects and mechanisms of Astragalus Membranaceus Injection (AMI) on mitophagy and mitochondrial function in chronic heart failure (CHF) based on phosphoproteomic and network pharmacology analysis. Primary neonatal mouse cardiomyocytes were isolated and hypertrophy cardiomyocyte model was induced by phenylephrine (PE) stimulation. AMI’s effects on cell size, apoptosis, mitophagy, and mitochondrial function in hypertrophic cardiomyocytes were assessed. A pressure-overload CHF model was established via transverse aortic constriction (TAC) surgery in C57BL/6N mice. Echocardiography and histopathology were employed to evaluate AMI’s effects on cardiac function and structural remodeling. Transmission electron microscope (TEM) and immunofluorescence were used to detect the distribution of autophagosomes and mitochondria. Phosphorylation-antibody microarray and network pharmacology were employed to explore AMI’s cardioprotective mechanisms. The AKT/mTOR pathway’s involvement was verified through Western blotting of AKTSer473 and mTORSer2481 phosphorylation and pharmacological validation using SC79 (AKT/mTOR activator) and GSK-690693 (AKT/mTOR inhibitor) in gain/loss-of-function experiments. In vitro, AMI dose-dependently suppressed pathological hypertrophy, attenuated apoptosis, restored mitochondrial function, and enhanced mitophagic flux. In vivo, AMI treatment significantly improved left ventricular ejection fraction while attenuated cardiac hypertrophy and interstitial fibrosis in TAC-induced CHF mice. Besides, AMI treatment increased the number of mitochondria and elevated autophagy in TAC mice. Phosphoproteomic screening and network pharmacology analysis identified the PI3K/AKT/mTOR axis as the primary regulatory pathway mediating AMI’s cardioprotection. Pharmacological activation of AKT/mTOR signaling using SC79 significantly suppressed mitophagic flux, whereas AMI treatment mirrored the effects of the AKT/mTOR inhibitor GSK-690693, effectively restoring mitophagy and mitochondrial homeostasis. AMI exerts its cardioprotective effects through inhibition of the AKT/mTOR pathway, thereby ameliorating maladaptive remodeling and mitochondrial dysfunction in CHF.


  • Open Access

    Shen Yuan Yi Qi Huo Xue capsules inhibit neutrophil NETosis by regulating the PAD4/NLRP3 signaling pathway to prevent heart failure after myocardial infarction

    by Yan-Jie Lian, He-Yi Zhang, Hong-Xu Liu, Ju-Ju Shang, Xiao-Lei Lai, Wen-Long Xing, Si-Nai Li


  • Open Access

    Multiple anthropometric characteristics and Brugada syndrome: A Mendelian randomization study

    by Sina Liu, Juju Shang, Hongxu Liu, Wenlong Xing, Wei Liu, Shenglei Qiu, Xiaolei Lai, Mingxuan Li, Siqing Wang

    Brugada syndrome (BrS) has been associated with lower obesity rates and reduced body mass index (BMI) in observational studies. This Mendelian randomization (MR) study investigates causal effects of anthropometric traits on the risk of BrS. Two-sample MR analyses were conducted using publicly available genome-wide association study summary statistics, and both discovery and replication datasets were incorporated. The inverse-variance weighted method was the primary analytical approach, supported by MR-Egger and weighted median methods. Sensitivity analyses (including Cochran Q test, MR-Egger intercept test, MR-PRESSO global test, and leave-one-out analysis) were performed to assess the robustness of the results. Genetically predicted comparative body size at age 10 showed significant inverse associations with BrS risk (discovery: odds ratio [OR] = 0.40, 95% confidence interval [CI]: 0.26–0.61, P = 2.07 × 10 −5 ; replication: OR = 0.47, 95% CI: 0.31–0.71, P = 3.68 × 10 −4 ). Similarly, adult obesity was inversely associated with BrS in the discovery set (OR = 0.78, 95% CI: 0.69–0.89, P = 1.42 × 10 −4 ). Genetically predicted childhood obesity, whole-body fat-free mass, BMI, waist-to-hip ratio, and basal metabolic rate also demonstrated potential protective effects (discovery: all P < .05). Reverse MR analysis revealed positive associations between genetically predicted BrS and both waist and hip circumference ( P < .005). This study suggests that genetically higher childhood/adult obesity and increased fat-free mass may reduce the risk of BrS. Maintaining a BMI in the upper-normal range and enhancing fat-free mass through resistance training may represent a viable strategy to mitigate BrS risk.